# PHERFLOT (NCT05504720)

> Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05504720
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Conditions: Esophagogastric Adenocarcinoma
- Interventions: Pembrolizumab; Trastuzumab; FLOT
- Enrollment: 31
- Primary outcome: Disease-free survival after 2 years co-primary endpoint
- Primary outcome: Pathological complete response rate co-primary endpoint

## Indexed commentary on PHERFLOT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 10
- YouTube: 3
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=pherflot-nct05504720

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05504720", "email": "<work email>"}; the inbox owner confirms by the emailed link.